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STUDY OF SOLUBLE FMS LIKE TYROSINE KINASE 1 AS PREDICTIVE         
                   MARKER OF PRE ECALMPSIA IN PRIMIGRAVIDA 
ABSTRACT :  
INTRODUCTION :   
Preeclampsia is pregnancy related disorder characterized by hypertension and proteinuria 
noticeable after 20 weeks of gestation.  It is a leading cause  of maternal and foetal 
mortality and morbidity. Preeclampsia affects 3-5% of all the pregnancies .  Soluble fms 
like tyrosine kinase 1, an anti angiogenic factor is involved in vasoconstriction and 
endothelial dysfunction responsible for the development of preeclampsia.      
AIM & OBJECTIVES :   
PRIMARY OBJECTIVE 
To find the association between soluble fms like tyrosine kinase 1 and incidence of 
preeclampsia in primi gravida. 
SECONDARY OBJECTIVE 
1.To determine the predictive value of soluble fms like tyrosine kinase 1 for 
preeclampsia. 
2.To determine whether early screening can be done  for preeclampsia using soluble fms 
like tyrosine kinase 1 
 
 
 
 
 MATERIALS AND METHODS :  
 This is a  prospective study conducted in Thanjavur medical college  hospital and allied 
institutions.  Blood and urine  samples were  collected from primigravida patients 
attending department of Obstetrics and Gynecology, TMCH/RMH and  analyzed for 
soluble fms like tyrosine kinase 1, liver enzymes , platelet count and urine for protein. 
Soluble fms like tyrosine kinase 1 is estimated by sandwich elisa method  
INCLUSION CRITERIA:                                                
All Primi Gravida  pateints attending department of obstetrics and gynecology, 
TMCH/RMH                                                
EXCLUSION CRITERIA  
Known cases of Diabetic , Hypertensive  and Hepatic disease 
 Known patients with proteinuria 
 Known patients with other organ dysfunction. 
DISCUSSION: 
Increase in  placental derived soluble fms-like tyrosine kinase 1 (sFlt-1) is responsible 
for the signs and symptoms of Preeclampsia, and increased  levels of these circulating 
markers are associated with  Preeclampsia. In our study,  we focused only on 
primigravida, because nulliparity itself is a main  risk factor for the development of   
Preeclampsia. If we look into distribution of study population according to Preeclampsia 
and SFLT levels through  Pearson’s Chi-square with continuity correction( 69.348, 
p value: <0.001), there is a statistically significant association between elevated SFLT 
levels and occurrence of Preeclampsia with 86.4% of Pre-eclampsia & Eclampsia 
patients showing elevated SFLT levels . 
 CONCLUSION    
              From this study, It is found that the primigravida   with increased serum sFlt 
levels   developed Preeclampsia in the later pregnancy and few of them developed 
Eclampsia also .  So , serum sFlt levels can be used to predict the occurrence of both 
Preeclampsia and also progression to Eclampsia. 
KEY WORDS :   
Preeclampsia, Eclampsia ,Primigravida, Soluble fms-like tyrosine kinase 1, 
12 
 
 
INTRODUCTION 
 
One of the important cause for maternal morbidity, mortality and 
perinatal morbidity & mortality is Gestational hypertension. WHO says, about 
16% of maternal death in developed countries is secondary to hypertensive 
disorders occurring during pregnancy
1
. This is significantly higher than other 
causes of maternal mortality viz 
Haemorrhage – 13% 
Abortion -13% 
Sepsis -2% 
Gestational hypertension is a significant factor accounting for 10 to 
38% maternal deaths in South Asia. In India, the maternal& perinatal mortality 
due to Preeclampsia has been reported to be 12% & 4.76% respectively
2,3
. Even 
in developed countries the case fatality rate has been reported to be 1.8% with 
Eclampsia and further 35% of women  develop  major complications.
4
 
Gestational hypertension is a disorder of abnormal placentation 
developing around 12 weeks of pregnancy. The main consequence of gestational 
hypertension is placental ischemia which leads to endothelial dysfunction , 
responsible for development of clinical symptoms and complications.  
13 
 
“Gestational hypertension”  is diagnosed when a pregnant women 
comes with a blood pressure of  more than or equal to 140/90 mmHg for the first 
time in mid pregnancy  [20 weeks] but proteinuria  not identified. 
In this, about half of them subsequently develop Preeclampsia 
syndrome characterised by proteinuria, thrombocytopenia and other symptoms 
and signs of end organs injury. 
Early detection of gestational hypertension and giving adequate 
antenatal care will definitely reduce both maternal and perinatal morbidity 
&mortality.  
An imbalance between angiogenic and anti angiogenic factors is 
responsible for etiopathogenesis of gestational hypertension. The biochemical 
factors for abnormal angiogenesis are “Placental growth factor” & “Soluble fms 
like tyrosine kinase 1”. These factors are more specific than measuring blood 
pressure and proteinuria
6
.  
 “Soluble vascular endothelial growth receptor 1” otherwise called 
“soluble fms like tyrosine kinase 1” antagonises vascular endothelial functions 
leading to hypertensive disorders of pregnancy
7
. 
In this study ,serum level of Soluble fms like tyrosine kinase 1 is 
evaluated in cases of primigravida with Preeclampsia  
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                      AIM & OBJECTIVES :   
 
PRIMARY OBJECTIVE 
To find the association between soluble fms like tyrosine kinase 1 and 
incidence of preeclampsia in primi gravida. 
 
SECONDARY OBJECTIVE 
1.To determine the predictive value of soluble fms like tyrosine kinase 1 
for preeclampsia. 
2.To determine whether early screening can be done  for preeclampsia 
using soluble fms like tyrosine kinase 1 
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REVIEW OF LITERATURE 
 
  “Hypertensive disorders of pregnancy” are one of the common 
medical complication occurring in pregnancy, accounting for 20% of all 
maternal deaths in India. Gestational hypertension is one of the unique disorder 
in pregnancy which disappears with delivery.  Gestational hypertension usually 
occurs after 20th week of gestation but the underlying mechanisms start as early 
as 8-18 weeks of pregnancy
30,31
. Gestational hypertension is one of the most 
common condition responsible for both maternal and perinatal morbidity and 
mortality
9
. 
 
 The working group of NHBPEP [National high blood pressure education 
programs2000] classified hypertensive disorders complicating pregnancy into 
four types 
5
.  
1. Gestational hyper tension,    
2. Preeclampsia & eclampsia  syndrome,  
3. Preeclampsia syndrome superimposed on chronic hypertension.  
4. Chronic hypertension 
 
Gestational hypertension 
Increased blood pressure occurring in the second trimester of 
pregnancy for the first time with the no proteinuria defines gestational 
hypertension.  
17 
 
Gestational hypertension -Criteria 
The increased blood pressure should be present on at least 2 
occasions, at least 4 hrs apart but within in a maximum of one week period . 
1. Systolic pressure ≥140mmHg and diastolic ≤90mmHg for the 1st time during 
pregnancy. 
2. Proteinuria not seen 
3.  Hypertension returns to normal before twelve weeks of postpartum.  
4. Absent intrauterine growth retardation and oligohydramnios by ultrasound 
Pre-eclampsia and eclampsia 
Onset of new hypertension and proteinuria after 20th week of 
pregnancy defines Preeclampsia. It leads to abnormalities of the coagulation 
system, cerebral ischaemia, renal failure, and disturbed liver function
10
. 
Preeclampsia is a disease with multisystem involvement and it is 
characterized by  proteinuria of  ≥ 300 mg in 24 hrs urine  sample. Clinically, 
Preeclampsia is classified as mild and severe. When signs and symptoms of end-
organ injury are  seen along with severe hypertension & proteinuria,  it  is  
severe Preeclampsia .  
 
    Also HELLP  syndrome  characterized by Low Platelets ,Elevated 
Liver enzymes and  Hemolysis  represents one  form of  severe Preeclampsia.  If 
the above findings are absent, Preeclampsia is called as mild. When 
18 
 
Preeclampsia is associated with seizures it is called Eclampsia, which is seen in 
0.1% of  all pregnancies,  while  Preeclampsia is seen in 3–5% of pregnancies. 
 
Both proteinuria and HT (hypertension) affects the endothelium which is main 
target of the disease. The hypertension of Preeclampsia is mainly characterized 
by decreased arterial compliance and peripheral vasoconstriction
24,25
. In patients 
having overt proteinuria around 10 percent develop Eclampsia. 
 
Criteria for Preeclampsia  in pregnant women 
Minimum criteria  
1.  BP  ≥140/90mmHg 
2.  Proteinuria  ≥300mg /24 hrs or > 1+  with dipstick  
 
Criteria for increased certainty for Preeclampsia  in pregnant women 
1.BP ≥ 160/110mmHg 
2. Serum creatinine >1.2 mg/dl  
3. Platelets <100000/mm3  
4.Proteinuria  ≥ 2g /24 hrs  or  >2+dipstick 
5.Increased Lactate Dehydrogenase  
6.Elevated liver enzymes levels  [ALT&AST] 
7.Maternal symptoms are persistent headache , epigastric  pain and visual  
 disturbances 
5
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HELLP SYNDROME -CRITERIA 
 
Pre-eclampsia superimposed on chronic hypertension 
Any new onset proteinuria after 20 weeks of pregnancy in women 
with chronic hypertension heralds the onset of Preeclampsia which is 
superimposed on chronic hypertension. 
 
Hemolysis–                   Serum bilirubin ≥1.2mg per dl  
LDH more than 600 U per L                  
Peripheral blood smear shows damaged  
                                 Erythrocytes like schistocytes and burr cells 
 
 
Liver enzymes                          ALT   increased 
                                              AST   increased  
 
Platelet count                   less than 100,000    per mm
3
 
Or 
Class 1: ≤50,000  per mm3 
Class2 : 50,000  but   ≤  100,000  per mm3 
                                             Class3  :  > 100,000  but  < 150,000 per mm3 
20 
 
 
About  30% of women with chronic hypertension may develop Preeclampsia.In 
uncomplicated  chronic hypertension, there is no proteinuria    
 
Criteria for  superimposed  Preeclampsia on hypertension  in pregnant 
women 
1. Newer onset proteinuria more than or equal to  300 mg in a 24 hrs urine 
sample of  hypertensive pregnant women after 20 weeks  of pregnancy . 
2. Any sudden increase in proteinuria in patients with pre-existing excretion of 
urine protein, sudden increase in blood pressure or decrease in platelet count less 
than 1,00,000/mm
3
 also indicates  superimposed  Preeclampsia on hypertension . 
 
Chronic hypertension 
Any pregnant patient coming before 20 weeks of pregnancy with a Blood 
pressure more than or equal to140/90 mmHg define chronic hypertension in 
pregnant women.  It is also associated with raised  perinatal and Maternal 
morbities. 
 
Chronic hypertension  in pregnant women-Criteria 
1.Blood Pressure more than or equal to140/90mmHg before   the onset of 
pregnancy or before 20 wks  pregnancy ( not attributed to gestational 
trophoblastic disease).  
21 
 
2. Hypertension persistent after 12 weeks delivery even when  diagnosed after 
20 weeks gestation. 
              Another rare entity is atypical Preeclampsia seen with all aspects of the 
syndrome but without hypertension or proteinuria, or both [sibai and 
stella,2009]
38
. 
Indicators of severity of Preeclampsia 
            Headaches and visual disturbances such as scotomata can be 
premonitory  symptoms of Eclampsia. Epigastric or right upper quadrant pain is 
due to hepatocellular necrosis or ischemia probably secondary  to stretching of 
Glissons’capsule. This pain frequently associated with elevated transaminase 
levels.             
Thrombocytopenia  is also an important  finding indicating worsening  
of Preeclampsia . It is due to platelet activation and aggregation as well as 
microangiopathic  haemolysis induced by vasospasm. Eclampsia incidence has 
decreased  over the years due to adequate prenatal care. 
 
INCIDENCE 
Hypertensive disorders of pregnancy occur in about 12-22% of pregnant women 
which is more prevalent (25% of nulliparous women are complicated by 
hypertensive disorders)
11
. 
Gestational hypertension is increased blood pressure occurring during 
pregnancy or within first 24 hours of delivery without features of Preeclampsia 
22 
 
or pre-existing hyper tension
8
.
   
Incidence in nulliparous & multi parous women 
is between 6%, 29% and 2%, 4% respectively. 
   The incidence increases with advanced age of gestation, with more 
than 50% of cases occurring in term (around 37 weeks pregnancy). Maternal and 
perinatal morbidities are increased.   
           Early onset gestational hypertension is often complicated by 
severe Preeclampsia.  Preeclampsia is considered primarily as a disease of  
primigravida
8
. Primigravida are also at higher risk of seizures.  Seizures can 
occur either antepartum (38%) &intrapartum (18%) or postpartum (44%)  
Antepartum seizures are more dangerous than postpartum seizures
16
. 
 
                      Preeclampsia produces severe  complications in the 
mother like acute renal failure, placental abruption, hepatic failure, intracranial 
haemorrhage, disseminated intravascular coagulation,  cardiovascular collapse  
and  in fetus prematurity, “Intrauterine fetal growth retardation” (IUGR), 
Intrauterine fetal death
12
.  Many Studies have shown that maternal and fetal 
mortality are significantly higher in nulliparous women with hypertensive 
disorders
13
. 
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Epidemiology of  gestational  Hypertension: 
Preeclampsia is one of the significant public health threat in both 
maternal and perinatal morbidity and mortality globally. 
                  It has been estimated that, 10 to 15% of direct maternal 
mortality (ie, due to  obstetric complications of pregnancy) are secondary to  
Preeclampsia & Eclampsia
44
 . In the United States of America, Preeclampsia and 
Eclampsia are one of leading cause of maternal death, along with 
thromboembolism, haemorrhage and cardiovascular problems
45-47
. There is 
about  one maternal death per 100,000 live births due to Preeclampsia 
/eclampsia, with a case-fatality rate  6.4 deaths per 10,000 cases
48, 49
. In 
Netherlands, over a study period of 12 years.  Preeclampsia was found to be the 
most common cause of maternal mortality, with 3.5 deaths per 100,000 live 
births
50
.  It occurs in about 2.5% of pregnant Japanese women 
51
. 
               In India, these hypertensive disorders account for 31% of maternal 
deaths, with 24.7% secondary to Eclampsia
64
. 
 
RISK FACTORS ; 
The risk factors include  [i] Family history of Preeclampsia, 
[ii]Primigravida, [iii]Higher incidence in pregnant women  with younger than 
20and older than 40 years,[iv] Twin pregnancy, triplets or more [v]Prolonged 
interval between pregnancies [vi]Obesity [vii] Gestational diabetes have a great 
risk of developing Preeclampsia as the pregnancy progresses and [viii]History of 
medical conditions such as chronic hypertension, migraine , rheumatoid  arthritis 
24 
 
,kidney disease , diabetes, periodontal disease during pregnancy and  urinary 
tract infections 
21
. 
 Other factors include Auto immune conditions, Environmental, 
Socioeconomic and  Seasonal influences [ Palmer, 1999]
68
. 
                             Two karyotypic anomalies hydatiform mole and trisomy 13 
are known to be associated with a risk for Preeclampsia. The association 
between trisomy 13 and Preeclampsia was first suggested in 1987 by Redman et 
al
4
. It was confirmed by a  larger retrospective study published in 1992 by 
Tuohy and James
43
. 
Advanced  maternal age and body mass index  are associated with 
increased risk for late Preeclampsia . Advanced maternal age alone is an 
independent risk factor for Preeclampsia
28   
. LCY Poon et al 
20
 study shows that 
the risk of late Preeclampsia  and gestational hypertension increases by 4% for 
every year over  the age of 32 years & by 10% for every 1 kg m
2
 above 24kg  m
2 
  
 
Obesity is characterized by expanded blood volume, increased 
cardiac output and an increase in oxygen consumption. Stroke volume and 
cardiac out put are increased to meet the increased metabolic demands. So 
hypertension results when systemic resistance fails to decrease as cardiac output 
increases
19
.  An elevated cardiac output in obese patients cannot tolerate   further 
increase   secondary to pregnancy associated haemodynamic alterations . So 
25 
 
they may develop hypertension with increased blood flow, exacerbating the 
endothelial injury leading to sequelae  of Preeclampsia 
19
. 
 
 
South Asians have a high prevalence of insulin resistance, elevated 
triglycerides and low high density lipoprotein levels 
20
. The metabolic 
abnormalities (glucose intolerance, hyperinsulinemia, hyper lipidemia) related 
with insulin resistance are also observed in women with  gestational 
hypertension . The markers of insulin resistance include Plasminogen Activator 
Inhibitor-1, Leptin, and TNF-alpha
33
. 
26 
 
                     Assisted   reproductive  techniques  increase the risk for 
Preeclampsia .because the maternal serum concentration of pregnancy 
associated Plasma Protein –A is reduced. So there is extensive evidence of 
linking low serum levels of pregnancy associated Plasma Protein –A with 
subsequent development Preeclampsia
20
. 
RISK FACTORS ASSESSMENT  WITH VARIOUS STUDIES
14 
 
Age 
Most of the studies suggest that women aged ≥ 40years particularly those with  
pre-existing chronic disease  has double  the risk of developing preeclampsia, 
whether they were multiparous or primiparous. (RR 1.68, 95% confidence 
interval, 1.23 to 2.29, and 1.96, 1.34 to 2.87, respectively)
 61
. 
 
Parity 
Nulliparae are three times at risk  for preeclampsia . (RR 2.35, 95% confidence 
interval 1.80 to 3.06)
 14
 . 
 
Previous preeclampsia 
History of preeclampsia in the first pregnancy is a risk  factor for development 
of  Preeclampsia /Eclampsia in   second pregnancy and  risk increases by seven 
times in the 2
nd
 pregnancy (RR  7.19, 95% confidence interval 5.85 to 8.83) 
14
. 
 
 
27 
 
Family history in  pre-eclampsia 
 History of preeclampsia in the family is a  risk  factor for development of  
Preeclampsia /eclampsia in  women. The risk increases by three times (RR 
2.90, 95% confidence interval 1.70 to 4.93)
14
.  
 
Multiple pregnancy 
Women who have twin pregnancy will have triple the risk of developing 
preeclampsia (RR  2.83, 95% confidence interval 1.25 to 6.40)
 33
. 
 
Pre-existing medical conditions 
Type 1 Diabetes— In patients with type 1 DM, the risk of developing  
preeclampsia raises by 4 times if diabetes is present before the onset of  
pregnancy (RR  3.56, 95% confidence interval 2.54 to 4.99) 
Pre-existing chronic Hypertension—one case-control study which is population 
based pointed out that, there is increased prevalence of chronic hypertension  
in women who developed Preeclampsia  than those  who did not (12.1% v 
0.3%)
14,37
.  
           Viral infections Parvo virus infections during  pregnancy leads to over 
expression of  an  anti angiogenic factor  “soluble fms like tyrosine kinase 1 ” 
responsible for development of Preeclampsia
22
 . 
 
Is There  Any Protection  For Preeclampsia   
Smoking  during pregnancy causes a variety of adverse outcomes, but 
it has been associated with  a reduced risk of  developing  hypertension during 
28 
 
pregnancy. It was speculated that potentially effective agents in tobacco smoke 
such as thiocyanate may have a hypotensive effect
62
, and nicotine was found to 
inhibit production of fetal thromboxane A2 
63
. 
 
Physiologic changes in normal Pregnancy:  
             In pregnancy  ,the cardiac output and blood volume increases 
by  about 40% and 50% respectively.  
Serum chemistry changes  associated with pregnancy:  
           Blood Urea Nitrogen decreases to < 10 mg/dl  
Creatinine decreases to < 0.7 mg/dl  
Uric acid decreases to< 4.0 mg/dl  
Serum albumin & haematocrit also decreases (due to hemodilution)  
during pregnancy. 
Plasma osmolality  and sodium are  decreased during pregnancy.   
Arterial blood gas analysis (ABG)show decreased pCO2  secondary to 
progesterone induced hyperventilation
29
. 
Hemodynamic and Volume Alterations in Preeclampsia. 
There is increase in cardiac after load and systemic vascular 
resistance in women with Preeclampsia. There is reduction in the levels of renin 
and aldosterone II in preeclamptic patients. As the preeclamptic patients have 
29 
 
reduced   plasma volume it becomes essential to maintain high levels of renin 
and aldosterone II 
Hormonal changes:  
                       Blood volume is mainly regulated by circulating levels 
of  catecholamine,  aldosterone  and renin angiotensin  system. There   is a 
paradoxical raise in all these hormones during pregnancy 
32
. 
 
       Increased renin secretion  from utero placental origin  stimulates  
the  adrenal aldosterone secretion. This rise in all levels leads to a decreased 
sensitivity to this vasoconstrictor, related to the marked increase in vasodilatory 
Prostaglandins in pregnancy.  
 
Renal Alterations in Preeclampsia. 
The GFR and renal blood flow are decreased in preeclamptic women. 
If proteinuria develops, a kidney biopsy if undertaken will typically show 
glomerular endotheliosis and cortical necrosis. This lesion is characteristic in 
preeclamptic women. Injury to the endothelium play a pivotal role in the 
pathology of Preeclampsia.
32
.  
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PATHOGENISIS OF PREECLAMPSIA 
 
 
 
31 
 
 
 
Role  of vasodilatory prostaglandins (PGE2 and PGI2):  
                            Vasodilatory   prostaglandins [PGE2  and  PGI2]  secreted  from 
placenta as well as other vascular endothelial origin and also decreased 
production of the vasoconstrictor prostaglandin  thromboxane.  Prostaglandins 
are derived from the precursor arachadonic acid and its structure consists of 20 
carbon fatty acids with a cyclopentane ring. PGI2 (prostacyclin) is a potent 
vasodilator and inhibitor of platelet aggregation. Thromboxane causes 
vasoconstriction and platelet aggregation. 
 
 
32 
 
Placental Ischemia 
The important pathophysiology in Preeclampsia is altered utero 
placental blood flow. Most studies about the pathogenesis of  this condition 
suggest  that a reduction in uterine blood flow is the main confounding  factor. 
There is uniformly abnormality in the placenta of  preeclamptic patients. The 
primary pathology appears to be at the maternal fetal interface and is 
characterized by poor trophoblastic invasion of the uterus. The endovascular 
invasion of the spiral arteries is incomplete. Specifically, the failure of the cyto 
trophoblasts to penetrate deep and cause a “widening of the pathway” appears to 
explain the relative reduction in utero placental blood flow.
32 
PATHOPHYSIOLOGY 
 
 
33 
 
 
 
NORMAL AND PRE ECLAMPSIA PLACENTAL 
STRUCTURE 
 
] 
 
34 
 
Placental structure 
In human placenta is  divided  into 
Basal part(maternal surface) 
Chorionic part (fetal surface) 
Amnion and the underlying chorion are membranes 
Gas and nutrients exchange takes place actively in terminal villous 
unit. Amnion, chorion are the 2 membranes that cover chorionic plate.  The 
chorionic arteries are collected at the umbilical cord [Kraus et al 2004]
58
. 
 
Formation of blood vessels 
           The first step in the production of blood vessels is the 
formation of branched vascular plexus. The primary vascular branched plexus 
forms by several processes, including the initial assembly of vascular precursor 
cells called angiogenesis 
 
                    Vascular plexus formation depends on the regulated 
expression of vascular endothelial growth factor (VEGF) by non-endothelial 
cells. This expression of VEGF modulates intracellular signalling pathways that 
regulate endothelial cell division, migration, and survival. VEGF and its two 
receptors, Flt-1 and Flk-1/KDR are crucial regulators of physiological and 
pathological blood vessel growth
23
.Invasive cyto trophoblasts express several 
angiogenic  factors and receptors, including VEGF-A, PlGF, andVEGFR-1 
(Flt1)
42
. Hence  blocking these angiogenic factors results in the development of 
Preeclampsia. 
35 
 
 
sFlt-1 inhibits placental growth factor signalling and which is also a 
potent inhibitor of “vascular endothelial growth factor”  which is  raised  in 
pregnant women with Preeclampsia
26
 
 
                During normal pregnancy, adequate oxygen and nutrient 
delivery to the developing utero placental unit occurs and remodel the maternal 
uterine spiral arteries. This process results in the conversion of the small-
diameter spiral arteries, high-resistance into high-capacitance, low-resistance 
vessels
17
. 
 
Placental formation during the early stage of pregnancy:  
                 sFlt1, Tie-1, Tie-2, (VEGFR-1),  and VEGFR-2 are 
essential for normal placental vascular development. Any Alteration in these 
factors in gestation leads to inadequate cytotrophoblast invasion seen  in the 
placentas of women with Preeclampsia
28
.  
            During implantation,  the uterine endometrium and  inner 
third of myometrium is invaded  by extra villous cytotrophoblasts. Invasive 
trophoblasts  express maternal endothelial cell markers such asCD31, αvβ3 
integrin, VCAM-1, and VE-cadherin (Zhou et al 1997
59
, 2002
60
).  
 The markers of endothelial activation are von Willebrand antigen , 
Cellular fibronectin , Soluble tissue factor, Soluble E-selectin, Platelet-derived 
growth factor, and Endothelin which is altered in women with Preeclampsia. 
 
36 
 
Endothelin 
                    Endothelin-1 (ET-1) has an important role in preeclampsia. ET-1 is 
a potent endothelium derived vaso constrictor.  Endothelin-1 acts in the  
endothelin type A (ETA)receptor in the vascular smooth muscle. Many studies 
indicating that the elevated levels of plasma ET-1 seen in the preeclamptic group 
and also circulating ET-1 level correlates with disease symptoms
39
. 
 
Soluble fms-like tyrosine kinase (sFlt1) has increased expression seen 
with decreased  expression of placental growth factor (PIGF) that impairs 
vascular endothelial growth factor (VEGF) signalling, were the first 
abnormalities  generated due to placental hypoxia/ischaemia, these factors target  
the maternal vascular endothelium of women  who  expected to develop  
Preeclampsia ( Krauss et al. 1997
55
, Gilbert et al. 2008
57
).  
 
                         These studies suggest that angiogenic imbalance could be a 
reliable marker of Preeclampsia and it allows detection before the onset of  
symptoms, and also angiogenic factors may be better markers of intrauterine 
growth retardation regardless of the presence or absence  of Preeclampsia
17.
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Factors responsible for microvascular dysfunction and 
Hypertension 
 
Immune factors and inflammation 
 
“Killer-cell immunoglobulin-like receptor” (KIR)  family of uNK 
cells and HLA-C genotypes of trophoblasts were found as immunogenic 
background in unsuccessful pregnancies  of Preeclampsia.  It is found that both 
fetal HLA-C2 haplotype and maternal KIR-AA genotype are associated with  
increased risk of Preeclampsia as per hybi et all
65
.  
 
Angiogenic factors 
           There is an imbalance between proangiogenic and antiangiogenic factors 
which is responsible for Preeclampsia. The important antiangiogenic factor  is 
sFlt-1.   sFlt-1 is a soluble splice variant of the VEGF receptor-1 and  it  
prevents the actions of proangiogenic molecules, such as VEGF and PlGF in 
target tissues
17
. 
                Molecular pathogenesis of Preeclampsia begins with the discovery of 
alterations in placental antiangiogenic factors. Hypoxia is an important 
regulator
28
.  In response to placental hypoxia, antiangiogenic factors released 
which enter the maternal blood stream . These antiangiogenic factors, such as 
sFlt1 and soluble endogolin, produce systemic endothelial dysfunction, resulting 
in increase in blood pressure, proteinuria, and the other systemic manifestations 
of Preeclampsia.  Exogenous administration of sFlt-1 has been shown to cause  
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SOLUBLE FMS LIKE TYROSINE KINASE – I  
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increase in blood pressure, affects glomerular endothelium (endotheliosis, a 
pathological renal lesion seen in Preeclampsia)  and produces proteinuria and in 
rats
66
. 
 
                 Pregnancy   associated Plasma Protein-A (PAPP-A) levels reduced an 
antenatal maternal serum biomarker, could  also be used as an early marker for 
pregnancies at-risk of Preeclampsia
67
.  
 
There is no appropriate specific screening test available till date 
which can predict the development of Preeclampsia. Serum concentrations of 
sFlt-1, PlGF and many other biomarkers of placental development have been 
suggested to have a predictive value to  help to identify women at risk
41
. 
However, there are few trials which studied the  utility of PlGF and sFlt-1 as 
biomarkers which can be used in both early  diagnosis and in  predicting who 
are those can  develop Preeclampsia
52
. 
 
“Soluble fms-like tyrosine kinase-1” (sflt-1)   
 sFlt-1, a splice variant of the vascular endothelial growth factor 
(VEGF) receptor, lacking the cytoplasmic and transmembrane domains, acts as a 
potent PlGF and VEGF antagonist . This protein acts by adhering to the 
receptor-binding domains of placental growth factor (PlGF) and vascular 
endothelial growth factor (VEGF), preventing their interaction with endothelial 
receptors on the cell surface and thereby inducing endothelial dysfunction , thus 
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preventing their availability to stimulate   angiogenesis and maintain endothelial 
integrity. sFlt-1 is produced by various tissues, including the troboblastic layer 
of  placenta  and  circulating monocytes .  
                    VEGF ligands and receptors are highly expressed by placental 
tissue in the first trimester.  In Preeclampsia, there is shallow trophoblast 
invasion and inadequate vascular remodeling leading to a relatively hypoxic 
environment and an increase in sFlt-1 production .  This increase in circulating 
levels of sFlt-1 reduce the  circulating levels of VEGF and promote endothelial 
cell dysfunction.   
 
               
         FLT1 gene encodes a member of the vascular endothelial growth factor 
receptor (VEGFR) family. VEGFR family members are having receptor tyrosine 
kinases (RTKs) which contain an extracellular ligand-binding region with seven 
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immunoglobulin  (Ig)-like domains, a transmembrane segment, and a tyrosine 
kinase (TK) domain within the cytoplasmic domain.  
 
The role of VEGFR1 has generally been characterised as a decoy 
receptor. It has been hypothesised that high levels of sVEGF-R1 antagonise the 
effects of VEGF and PlGF on placental development, vascularisation and 
maternal endothelial cell function, and thus the increase in sVEGFR1 in 
maternal plasma has been postulated to inhibit VEGF-A. However, VEGF-A 
induces increased vascular permeability, vasodilatation and angiogenesis.  
                 Increased sVEGFR1 should therefore prevent the 
permeability responses of Preeclamptic plasma, not induce them. Thus increased 
sVEGFR1 acting on VEGF-A by itself does not explain the symptoms of 
preeclampsia or experimental findings of the effect of Preeclamptic plasma, but 
sVEGFR1 acting on PlGF, and removing the inhibition of VEGF would explain 
the symptoms.  
Soluble fms-like tyrosine kinase-1 binds to VEGFR-1, VEGFR-2 and 
placental growth factor  plays an important role in angiogenesis and 
vasculogenesis. Increased sVEGFR-1 levels were seen  in  the placenta, plasma 
and serum  of preeclamptic women.  
            The magnitude of the imbalance between angiogenic (VEGF) and 
antiangiogenic factor (sVEGFR-1) concentrations in maternal blood is greater in 
early-onset (severe) than in late-onset (mild) Preeclampsia 
23
. 
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THE VASCULAR ENDOTHELIAL GROWTH FACTOR  FAMILY 
                              Vascular endothelial growth factor was first  isolated in 
ascitic fluid.  It was first termed as Vascular Permeability Factor in 1983 due its 
ability to increase vascular permeability .It promotes endothelial cell 
proliferation.  
 
THE VASCULAR ENDOTHELIAL GROWTH FACTOR  RECEPTORS 
                  Vascular endothelial growth factor receptor-1 (VEGFR-1) (or fms-
like tyrosine kinase-1 (flt-1)) andVEGFR-2 (kinase insert domain-containing 
receptor or fetal liverkinase-1)
23
arethe vascular endothelial growth factor  
receptors. This family contains five members in humans, VEGF-A, -B, -C, and -
D and Placental Growth Factor (PlGF). The most widely studied form is VEGF-
A (or simply VEGF), is expressed as numerous isoforms secondary to  
alternative exon splicing resulting in mature proteins varying from 121 to 206 
amino acids
18
.  
 
                It exerts its  biological effects through two high-affinity tyrosine 
kinase receptors that is, VEGFR-1 andVEGFR-2. VEGFR-1 has 10-fold higher 
affinity than VEGFR-2 for VEGF binding, but VEGFR-2 has a more important 
functional role in mediating signalling events involved in endothelial cell 
mitogenesis, migration, survival and vascular permeability
23
. sFlt-1 is a 
circulating soluble receptor for both VEGF and PlGF, which when increased in 
maternal plasma leads to less circulating free VEGF and free PlGF,  
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VEGF and VEGFR   expression in Preeclampsia 
VEGF 
                   Abnormally high levels of VEGF in Preeclamptic plasma and serum 
amniotic fluid, umbilical cord serum and urine have been described using 
radioimmunoassay or competitive enzyme immunoassay 
                       VEGF is a well-known promoter of angiogenesis; it also induces 
nitric oxide and vasodilatory  prostacyclins in endothelial cells, suggesting a role 
in decreasing vascular tone and blood pressure implicated in glomerular healing, 
and anti-VEGF compounds in addition to its role in Preeclampsia it also  
increase apoptosis, impair glomerular capillary repair, and increase proteinuria 
in patients with mesangioproliferative nephritis . 
 
Placental Growth Factor 
 
PlGF is a 45-to 50-kd dimeric glycoprotein with 53% sequence 
identity to VEGF.  It has  PlGF- 1 and PlGF-2 protein isoforms. The decrease in  
PlGF production is the reason for  abnormalities of placental angiogenesis which 
man be through effects on other vascular growth factors. Decreased 
concentrations of circulating free PlGF and free VEGF have been noted during 
clinical Preeclampsia and even before its onset. Many studies, say that PlGF is 
reduced in women with Preeclampsia
53,54
.  
                The reason for low levels of PIGF was found to be due to its binding 
with sFlt-1 rather than reduced production by the Preeclamptic placenta.  
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Endogolin 
Soluble Endogolin (sEng) plays an important role in the 
pathophysiology of Preeclampsia. Endogolin is a pro-angiogenic factor that 
protects endothelial cells under hypoxia and regulate NO (nitric oxide) 
dependent vasodilatation . 
 
Preeclamptic placentas  overexpress sFlt1 and sEng mRNAs as well 
as sFlt1and sEng proteins. On the other hand, Soluble Endogolin (sEng) is an 
anti-angiogenic protein. It consists of the extra cellular part of the molecule that 
may be produced through the proteo-cleavage of the placental membrane-bound 
form. It decreases endothelial nitric oxide by inhibiting TGF signalling and this 
leads to endothelial dysfunction. 
                  In vitro, Soluble Endogolin  acts as a negative regulator of 
angiogenesis by competitive interaction with TGF, thereby impairing capillary 
formation by endothelial cells.  
 
 
                  Furthermore, it induces high arterial pressure and vascular 
permeability in pregnant rats in which the protein was over-expressed. Very 
interestingly, the introduction of Endogolin in the pregnant animals induced 
renal, placental and hepatic changes reminiscent of the HELLP syndrome . 
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               Soluble endogolin could be used as a biochemical marker for 
prediction of PE in the second trimester, as it is usually increased 10-12 weeks 
before the clinical symptoms of the disease manifest itself. 
 
           Soluble endogolin is present in substantial excess in Preeclampsia, 
patients compared to normotensive controls however whether this factor is 
specific for Preeclampsia or it is also increased with other hypertensive diseases 
of pregnancy such as gestational or chronic hyper-tension is the aim of future 
studies which are needed to clarify this issue.  
 
                 The concentration of Soluble Endogolin  appear to increase with the 
severity of Preeclampsia, especially in Preeclampsia,  complicated by HELLP 
syndrome and IUGR. However, prediction of cut-off value for Preeclampsia, 
and gestational hypertension was not attempted due to the non-consistent results 
of studies assessing Soluble Endogolin  level.  
 
Some of these studies showed variable Soluble Endogolin  level in 
pregnancies complicated by Preeclampsia, different factors affecting Soluble 
Endogolin  level either related to the race or the BMI are still investigated so this 
point is still a point of discussion and needs further studies.   
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            This signalling pathway shows elevated circulating and placental levels 
of the soluble form of the VEGF receptor, fms-like tyrosine kinases (sFlt)-1.  
Nitric oxide 
              VEGF is a proangiogenic factor that stimulates NO production and 
endothelial NO synthase (NOS) protein levels
40
. NO production is elevated in 
normal pregnancy and play an important role in the vasodilatation. 
 
Sandrim et al
69
  study indicates that women with Preeclampsia have 
reduced plasma and whole blood nitrite levels, which negatively correlate with 
the potent VEGF inhibitor sFlt-1.  
 
Facemire et al
70
 demonstrated that inhibition of VEGF receptor  type 
2 (VEGFR2) results in hypertension through impaired NO synthesis and 
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contributes to the enhanced ET-1 production and elevations in blood pressure in 
response to sFlt-1-induced  hypertension in pregnant 
rats
39
.
 
 
              In view of diagnosing the condition , the development of soluble 
angiogenic markers discussed above  help  in the screening  and early diagnosis 
of Preeclampsia.  
             The purpose of this study is to use  sFlt-1 as a predictive marker of 
Preeclampsia   in early  trimester. 
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MATERIALS AND METHODS 
 
The study was carried out in a tertiary care centre, Raja Mirasudar 
Hospital, Thanjavur, attached to our Medical College. 90 primigravida were 
included in the study.  
The diagnosis of gestational hypertension was done as per the norms of 
American college of Obstetrics and Gynecologists.  
 
All the participants   were inquired by a questionnaire  
1) Name of the person 
2) Age of the person 
3) Address 
4) Complaints 
5) Last Menstrual period 
6) Head ache                                                                   
7) Inability to tolerate Bright light, Blurred vision                                                        
8) Double vision           
9) Nausea, Vomiting                                                      
10) Right sided upper Quadrant pain       
11) Epigastric pain 
12) Dyspnoea 
13) Oliguria                                                            
50 
 
14) Bleeding tendency 
15) Sudden weight gain 
16) Edema 
17) Tiredness 
 
FAMILY HISTORY 
1) Preeclampsia 
2) Twins                                                                   
3) Hypertension 
4) Diabetic 
 
DRUG HISTORY: 
1) Thiazides                                                          
2) Retinoid                                                              
3) Anti  retro viral therapy 
4) Estrogen 
5) β-blockers                                                           
6) Progestin 
7) Glucocorticoids 
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INCLUSION CRITERIA:                                                  
1) Age between  20-45 
2) Primi Gravida                                                    
3) 16-20   Weeks of pregnancy  
EXCLUSION CRITERIA  
1) Known Diabetic, Hypertensive  
3) Edema 
4) Proteinuria, oliguria 
5) Hepatic disease  
6) Involvement of other Organs. 
 
Clinical examination of participants were carried out to rule out Diabetes,  
Hypertension,  edema, proteinuria, oliguria, Hepatic disease, involvement of 
other Organs.  
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METHODOLOGY 
BLOOD COLLECTION:-  
Informed consent was obtained for each primigravida prior to the 
study. 5ml of blood samples were collected by vene puncture under strict aseptic 
precaution as per the inclusion criteria. The samples were centrifuged and serum 
separated. One part of the sample was taken and analysis of ALT,AST, 
Creatinine & Platelet count were done immediately. Remaining part of the 
sample was stored for analysis of at - 70º C. Enzyme-linked immunosorbent 
assays (ELISA) for sFlt-1was performed with commercially-available kits.  
In sterile tubes urine samples were collected and tested for protein with dipstick 
method. 
ANALYSIS OF BLOOD SAMPLES:  
The serum collected above was used for the estimation of the 
following parameters  
ESTIMATED PARAMETERS: 
1. Soluble fms like tyrosine kinase 1 by Elisa method 
2. Serum Aspartate Transaminase - Modified IFCC Method. 
3. Serum Alanine Transaminase - Modified IFCC Method. 
4. Serum Creatinine - Modified Jaffe’s Method  
5. Platelet count  -  cell counter 
6. Urine protein – dipstick method 
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7. Blood pressure  measured by sphygmomanometer 
8. weight 
Gestational Hypertension - defined as diastolic blood pressure ≥ 
90mmHg and systolic blood pressure  ≥  140mmHg in normotensive patients 
after 20 weeks of pregnancy  at least two consecutive measurements 6 hrs apart 
urine protein measured by dipstick method on a random urine sample. 
ESTIMATION OF “SOLUBLE FMS LIKE TYROSINE KINASE 1” 
METHODOLOGY : 
    Enzyme-linked immune sorbent assay (ELISA) 
PRINCIPLE : 
                    The basis of ELISA used by this kit is Biotin double antibody 
sandwich technology to assay human  “soluble fms like tyrosine kinase 1”. 
Samples & calibrators containing  “soluble fms like tyrosine kinase 1”  were 
added to the wells that are pre-coated with an anti humans VEGF –R1 antibody  
and then incubated. Then biotin-labelled anti human   sVEGF –R1antibody was 
added which unites with streptavidin-HRP forming immune complexes. The 
unbound enzymes were removed after incubation by washing. TMB Substrate 
was added which changes the colour of the solution to blue and then yellow by 
the effect of acid. The shades of solution positively correlate with the 
concentration of human   sVEGF –R1antibody. 
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MATERIALS SUPPLIED IN THE KIT: 
1. Human sVEGF –R1 Standard lyophilised, 1000pg/ml upon reconstitution 
2. Standard dilution - 3ml 
3. Mono clonal antibody to Human sVEGF – R1Coated ELISA plate  
4. Streptavidin-HRP - 6ml, Conjugate diluent (20ml) 
5. Washing concentration (30X) - 20ml 
6. Assay buffer concentration (20X) 5ml 
7. Human sVEGF –R1 antibodies labelled with biotin - 1ml 
8. Stop solution - 6ml    (1M Phosphoric acid) 
Other materials required were 
1. 37°C incubator 
2. Precision pipettes and disposable pipette tips 
3. Disposable tubes for sample dilution 
4. Standard enzyme reader 
5. Distilled water 
6. Adsorbent paper 
PREPARATION OF REAGENTS 
All samples and reagents were brought to room temperature which 
takes about 30 minutes. Specimens were mixed thoroughly by gentle inversion 
and visible particulate matter was cleared by low speed centrifugation. 
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• Wash buffer: 20x wash solution was diluted by pouring the total contents 
of the bottle (50ml) into a 1L graduated cylinder and 950ml of deionised water 
was added to make a final volume of 1000ml. It was then thoroughly mixed. 
 Assay buffer:   20x assay buffer solution was diluted by pouring the total 
contents of the bottle (5ml) into a 100ml graduated cylinder and 95ml of 
deionised water was added to make a final volume of 100ml. It was then 
thoroughly mixed.    
 Dilution of standard solution : The kit had a standard of original 
concentration which was supposed to be diluted in small tubes by following 
the instructions: 
Seven  tubes one for each standard pointS1,S2,S3,S4,S5,S6,S7 was labelled. 1:2   
serial dilutions were prepared. 
225 µl of assay buffer   pipetted  into each tube. 225µl of 
reconstituted standard  pipetted  into the first  tube, labelled S1,and mixed. 225 
µl of reconstituted standard pipetted  into the second tube, labelled S2,and 
mixed. 225 µl of  reconstituted  standard  pipetted into the third tube, labelled 
S3,and mixed. 225 µl of  reconstituted  standard  pipetted  into the fourth tube, 
labelled S4,and mixed. 225 µl of  reconstituted  standard  pipetted  into the fifth 
tube, labelled S5,and mixed.225 µl of  reconstituted  standard pipetted into the 
six tube, labelled S6,and mixed. 225 µl of  reconstituted  standard  pipetted  into 
the seven tube, labelled S7,and mixed. 225 µl fromS7 labelled tube pipetted & 
Discarded. 
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                            S1           S2         S3            S4          S5        S6         S7 
 
      Streptavidin-HRP : ready to use 
• Biotin labelled Human sVEGF – R1antibodies : ready to use 
• Stop solution : ready to use 
ASSAY PROCEDURE 
                  The number of stripes needed was decided by the number of samples 
to be tested and by that of standards. 
1. Blank well: no sample, 100 µl assay buffer  was added to the blank well.  
2. Standard solution well: 50μl standard and 50μl assay buffer were added.  
3. Sample well: 50μl sample, 50μl assay buffer were added.  
4.      50μl of  biotin conjugate was added to all wells 
 
STANDARD 
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The plate was shaken gently to mix them up and then it was 
incubated at 25°C for 120 minutes. Then the ELISA plate was covered with a 
seal plate membrane. 
Washing: 
      The ELISA plate was covered by a seal membrane ,which the was carefully 
removed and drain the  liquid was drained . Each well was filled with 350μl 
wash solution. After standing for 30 seconds, the liquid was drained. To blot the 
ELISA plate, it was pat hard on bibulous papers on the test bed, several times 
downward.  The procedure was repeated 6 times. 
4. 100 μl of  Streptavidin-  HRP conjugate to all wells. Then the ELISA plate 
was covered with a seal plate membrane. They were mixed by gentle shaking. 
Incubation was done for 60 minutes at 25°C away from light. 
Washing : 
The ELISA plate was covered by a seal membrane, which the was 
carefully removed and the  liquid was drained. Each well was filled with 350μl 
wash solution. After standing for 30 seconds, the liquid was drained. To blot the 
ELISA plate, it was pat hard on bibulous papers on  the test bed, several times 
downward.  The procedure was repeated 6 times. 
100 μl of  TMB Substrate solution was added to all wells. 
Incubated at 25°C for 30 minutes. 
  Direct exposure  to intense light was avoided. 
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• Stop : To stop the solution 50μl stop solution was added to each well. At 
this moment, there was an immediate change in colour from blue to yellow. 
• Assay : Taking blank as zero, the absorbance (OD) of each well was 
measured at 450nm wavelength within 10 minutes after adding the stop solution.  
• According to the concentration of standards and their corresponding  OD 
values, the linear regression equation of standard curve was calculated. Then the 
concentration of the sample was calculated according to their corresponding OD 
values.  
 
CALCULATION OF RESULTS 
Calibration graph : The standard curve was constructed by plotting 
concentration of each Human sVEGF – R1   in ng/ml along the x-axis against 
the OD values of the corresponding calibrator along y-axis. 
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Human sVEGF – R1 values of samples : 
The Human sVEGF – R1   concentration of each sample was found by locating 
the point on the curve corresponding to the absorbance values for the samples 
and reading its corresponding concentration in ng/ml from the x-axis. 
ASSAY RANGE :  45pg/ml  to 1500pg/ml 
SENSITIVITY : 0.1pg/ml 
VALIDITY&STORAGE : 
         serum samples were 6 months when stored at 2-8°C and 12months at -
20°C. 
QUANTITATIVE ESTIMATION OF SERUM CREATININE 
MODIFIED JAFFE’S REACTION, INITIAL RATE 
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PRINCIPLE OF THE METHOD 
                 Creatinine reacts with picric acid in an alkaline medium to form an 
orange-yellow colour which is termed as Jaffe’s reaction. The initial rate method 
is introduced to improve the specificity of the test. The optical density of the 
orange-yellow colour formed is directly proportional to the concentration of 
creatinine, which is measured photometrically at 500 to 520nm. 
REAGENT COMPOSITION 
 Reagent 1 - Picric Acid  
                   25.8 mmol/L 
 Reagent 2 - Sodium Hydroxide  
                   95 mmol/L 
 Creatinine standard : 2 mg/dl  or (0.166 mmol/L) 
 
 
REAGENT PREPARATION 
    Equal volumes of Reagent 1 and Reagent 2 are mixed and wait for 15 minutes 
before use.  
 
STORAGE AND STABILITY 
                   Reagents 1, 2 and standard when unopened remain stable till the 
expiry date. The Working Reagent is stable for 21 days at 2-8°C. The 
absorbance of the reagent blank should be <0.3 at 505nm when read against 
distilled water. 
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ASSAY PARAMETERS 
Wavelength (nm)        : 505 
Mode                 : fixed time 
Sample volume          : 100 μl 
Reagent volume         : 1000 μl 
Lag time               : 20 sec 
Kinetic interval         : 60 sec 
No. of readings         : 1 
Reaction temperature    : 37°C 
Normal low            : 0.6 mg/dl 
Normal high           : 1.4 mg/dl 
Reaction direction       : increasing 
Linearity low          : 0 mg/dl 
Linearity high          : 25 mg/dl 
Absorbance limit (max)  : 0.3 
Standard concentration: 2 mg/dl 
Blank with            : water 
Units                 : mg/dl 
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ASSAY PROCEDURE 
 
PIPETTE STANDARD TEST 
Working reagent 1000μl 1000μl 
Standard 100μl - 
Test - 100μl 
 
Mixed well and read the initial absorbance within 20 seconds of mixing and 
final absorbance at 80 seconds. 
 
CALCULATION  
The results are calculated as follows : 
ΔA = A2 - A1 
 
 
Creatinine concentration in mg/dl = ΔA of the test      ×    concentration  of                                                  
                                                          ΔA of standard           standard(mg/dl) 
                                                                                                           
                                                                    
LINEARITY 
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                The assay is linear upto a value of 25mg/dl. For higher values the 
samples were diluted with normal saline and the assay repeated. Then the results 
were multiplied with the dilution factor.  
 
NORMAL VALUES 
For males   : 0.7 - 1.4 mg/dl 
For females : 0.6 - 1.2 mg/dl 
 
ESTIMATION OF ASPARTATE TRANSAMINASE: (AST) 
METHOD: MODIFIED IFCC METHOD  
PRINCIPLE: Aspartate transaminase (AST) catalyses the transfer of amino 
group from L-aspartate to α –ketoglutarate to yield oxaloacetate and L- 
glutamate. The oxaloacetate undergoes reduction with simultaneous oxidation of 
NADH to NAD in the malate dehydrogenase catalysed indicator reaction. The 
resulting rate of decrease in absorbance at 340nm is directly proportional to the 
AST activity.  
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L – Aspartate + α –ketoglutarate                                   oxaloacetate + L-
glutamate  
 
Oxaloacetate + NADH + H+                                           Malate +NAD
+
 
 
REAGENT:1 
Tris buffer (pH 7.8) 20mmol/L  
L-Aspartate 230mmol/L  
LDH >33.3μkat/L  
2-Oxaloacetate 13.21mmol/L  
MDH >33.3μkat/L  
REAGENT: 2  
NADH 1.51 mmol/L  
REAGENT PREPARATION:  
Working reagent was prepared by mixing 4 parts of R1 with 1 part of R2 per 
assay tube.  
PROCEDURE:  
Aspartate 
transaminase                      
malate dehydrogenase 
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500 μl of working reagent was mixed with 25μl of sample , mixed well and 
aspirated.  
CALCULATION:  
SGOT (AST) activity (IU/L) = DA/ min x factor (3376)  
NORMAL RANGE: 10 – 40 U/L 
 
ESTIMATION OF ALANINE TRANSAMINASE: (ALT)  
METHOD: MODIFIED IFCC METHOD  
PRINCIPLE: Alanine transaminase (ALT) catalyses the transfer of amino 
group from L-alanine  to α –ketoglutarate to yield pyruvate and L- glutamate. 
Pyruvate in the presence of NADH   and lactate dehydrogenase  is reduced to L-
lactate. In this  reaction  NADH is oxidized to NAD. 
 
 
L – Alanine+ α –ketoglutarate                                     Pyurvate + L-glutamate  
 
Pyruvate  + NADH + H+                                          Lactate + NAD+ 
REAGENT:1 
Tris buffer (pH 7.8)               100mmol/L  
Alanine  transaminase 
Lactatedehydrogenase 
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L-Alanine                            230mmol/L  
LDH                                       > 4U/ml  
α- ketoglutarate                 13.20mmol/L  
REAGENT: 2  
β  NADH                      1.52 mmol/L  
REAGENT PREPARATION:  
Working reagent was prepared by mixing 4 parts of R1 with 1 part of R2 per 
assay tube.  
PROCEDURE:  
500 μl of working reagent was mixed with 25μl of sample , mixed well and 
aspirated.  
CALCULATION:  
SGPT(ALT) activity (IU/L) =              A/ min x factor (3376)  
NORMAL RANGE:  
For women:  up to 32 U/L 
For men     :  up to  65U/L 
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RESULTS  & STATISTICS 
 
                                Our study is population based cohort study. The  data were 
collected prospectively during pregnancy.  In addition, the study was restricted 
to primigravida , The incidence  and risk factors for Preeclampsia and 
gestational hypertension  are increased with primigravida. Preeclampsia can be 
predicted by measuring serum level of sFlt-1  at a stage when the syndrome is 
clinically unrecognizable. In our study , primigravidae were selected, since 
nulliparity itself is a risk factor for the development of   Preeclampsia. 
 
             Previous studies have shown that nulliparity increases the risk of 
developing Preeclampsia up to three-fold. Women who had any other known 
risk factors for developing Preeclampsia were excluded from the study. Smokers 
were also not included in the study because this has been shown to alter the sFlt-
1 levels. 
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Table 1 Age distribution of the study population (n=90) 
 
Age group Frequency Percent 
21- 25 years 52 57.8 
25 - 30 years 38 42.2 
Total 90 100.0 
 
Mean age: 24.92 years.                    Standard deviation: 2.309 
years 
Maximum: 30 years 
Minimum: 21 years 
Figure 1:Pie chart showing age distribution of the study population (n=90) 
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Table 2 Distribution of the  mean maternal weight in kg during various 
antenatal periods (n=90) 
Statistic 
Mean maternal weight in kg 
17 to 20 
weeks 
21 to 28 
weeks 
29 to 36 
weeks 
36 to 40 
weeks 
Weight Gain during 
pregnancy 
Mean 59.67 60.94 65.94 71.98 12.31 
Std. Deviation 4.490 4.171 4.090 3.828 2.048 
Minimum 45 47 49 55 8 
Maximum 67 66 73 79 18 
 
The mean weight gain during pregnancy of the study population was 12.3 kg 
Figure 2:Line diagram showing mean maternal weight in kg during various 
antenatal periods (n=90) 
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Table 3 Distribution of the Mean maternal blood pressure during various 
antenatal periods (n=90) 
 
Systolic Blood pressure Mean 
Standard 
Deviation 
Minimum Maximum 
17 to 20 weeks 117.60 6.97 102.00 132.00 
21 to 28 weeks 106.80 14.25 90.00 156.00 
29 to 36 weeks 116.38 13.90 90.00 160.00 
36 to 40 weeks 120.96 15.37 102.00 156.00 
Difference between 1
st
 and 4
th
 
reading 
3.36 12.23 -16.00 40.00 
Post-natal period 117.02 8.50 102.00 136.00 
 
Diastolic Blood pressure Mean 
Standard 
Deviation 
Minimum Maximum 
17 to 20 weeks 82.34 3.80 76.00 89.00 
21 to 28 weeks 74.89 11.31 60.00 104.00 
29 to 36 weeks 82.89 8.68 70.00 110.00 
36 to 40 weeks 84.62 10.78 76.00 110.00 
Difference between 1
st
 and 4
th
 
reading 
2.28 9.70 -9.00 34.00 
Post-natal period 80.89 5.69 60.00 90.00 
 
Mean systolic pressure raised by 3 mmHg  and mean diastolic pressure raised  
by 2 mmHg during pregnancy. 
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Figure 3:Line diagram showing Mean maternal blood pressure during 
various antenatal periods (n=90) 
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Table 4 Distribution of the Mean maternal levels of transaminases during 
various antenatal periods (n=90) 
ALT Mean 
Standard 
Deviation 
Minimum Maximum 
17 to 20 weeks 26.79 3.78 22 38 
21 to 28 weeks 29.31 5.06 23 47 
29 to 36 weeks 28.97 10.13 22 68 
36 to 40 weeks 29.71 10.13 23 70 
Difference between 1st and 4th 
reading 
2.92 8.11 -6.00 37.00 
AST Mean 
Standard 
Deviation 
Minimum Maximum 
17 to 20 weeks 27.33 3.75 22 38 
21 to 28 weeks 28.60 6.21 23 53 
29 to 36 weeks 29.12 10.06 22 69 
36 to 40 weeks 29.33 9.92 22 68 
Difference between 1st and 4th 
reading 
2.00 7.73 -10.00 34.00 
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Figure 4:Line diagram showing Mean maternal transaminase levels during 
various antenatal periods (n=90) 
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Table 5 Distribution of the Mean maternal levels of Serum creatinine 
during various antenatal periods (n=90) 
 
Serum creatinine levels Mean 
Standard 
Deviation 
Minimum Maximum 
17 to 20 weeks 1.16 2.94 0.60 28.00 
21 to 28 weeks 0.87 0.06 0.80 1.10 
29 to 36 weeks 0.88 0.10 0.80 1.20 
36 to 40 weeks 0.92 0.12 0.80 1.30 
Difference between 1st and 4th 
reading 
-0.24 2.91 -26.80 0.40 
 
Figure 5:Line diagram showing mean serum creatinine levels during 
various antenatal periods (n=90) 
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Table 6 Distribution of the Mean maternal platelet count during various 
antenatal periods (n=90) 
Platelet count Mean 
Standard 
Deviation 
Minimum Maximum 
17 to 20 weeks 159381.9 6829.7 150085.0 176676.0 
21 to 28 weeks 153245.7 9302.0 98654.0 172538.0 
29 to 36 weeks 150519.1 18546.0 56000.0 170467.0 
36 to 40 weeks 149049.8 18397.3 67567.0 176069.0 
Difference between 1st and 4th 
reading 
-10332.1 18755.0 -92889.0 17974.0 
 
Figure 6:Line diagram showingmean platelet count during various 
antenatal periods (n=90) 
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Table 7 Distribution of the proteinuria during various antenatal periods 
(n=90) 
 
Urinary protein Count Column N % 
 
17 to 20 weeks 
 
Nil 69 76.7% 
Trace 21 23.3% 
21 to 28 weeks 
Nil 81 90.0% 
Trace 4 4.4% 
1+ 1 1.1% 
2+ 4 4.4% 
29 to 36 weeks 
 
Nil 74 82.2% 
Trace 2 2.2% 
1+ 3 3.3% 
2+ 8 8.9% 
3+ 1 1.1% 
4+ 2 2.2% 
37 to 40 weeks 
Nil 69 76.7% 
1+ 5 5.6% 
2+ 5 5.6% 
3+ 6 6.7% 
4+ 5 5.6% 
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Figure 7 Showing proteinuria during various antenatal periods (n=90) 
 
 
There is increased proteinuria with corresponding gestational age in 
Preeclamptic and Eclamptic patients. 
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Table 8 Distribution of the “soluble fms like tyrosine kinase 1” in the study 
population (n=90) 
 
Descriptive statistic 
“Soluble fms like tyrosine kinase 1”  
(sFlt in pg/ml) 
Mean 188.50 
Std. Deviation 176.005 
Minimum 76 
Maximum 1409 
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SFLT levels Frequency Percent 
Normal 
(75 to 179 pg/ml ) 
71 78.9 
Elevated 
(> 179 pg/ml) 
19 21.1 
Total 90 100.0 
 
 
Figure 8 Pie chart showing the levels of “soluble fms like tyrosine kinase 1” 
(n=90) 
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Table 9 Distribution of the study population according to pre-eclampsia 
(n=90) 
 
Medical condition Frequency Percent 
Normal 68 75.6 
Pre-eclampsia 17 18.9 
Eclampsia 5 5.6 
Total 90 100.0 
Figure 9 Pie chart showingdistribution of the study population according to 
eclampsia (n=90) 
 
The “soluble fms like tyrosine kinase 1”  levels were raised  in 21% of the 
subjects with a mean level of 188.5 ± 176.0 pg/ml 
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Table 10 Distribution of the study population according to pre-eclampsia 
and SFLT levels (n=90) 
SFLT levels 
Normal blood 
pressure 
N (%) 
Pre-eclampsia & 
Eclampsia 
N (%) 
Total 
N (%) 
Normal 
(75 to 179 pg/ml) 
68 (100) 3 (13.6) 71(78.9) 
Elevated 
(> 179 pg/ml) 
0 (0) 19 (86.4) 19 (21.1) 
Total 68 (100) 22 (100) 90 (100) 
 
 
 
Figure 10 Bar chart showing distribution of the study population according 
to pre-eclampsia and SFLT levels (n=90) 
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Table 11 Distribution of the study population according to pre-eclampsia 
and SFLT levels (n=90) 
SFLT levels 
Normal blood 
pressure 
 
Pre-eclampsia & 
Eclampsia 
 
Total 
Normal 
(75 to 179 pg/ml) 
N (%) 
68 (95.8) 
 
3 (4.2) 71(100) 
Elevated 
(> 179 pg/ml) 
N (%) 
0 (0) 19 (100) 19 (100) 
Total N (%) 68 (100) 22 (100) 90 (100) 
 
Relative risk = 100/4.22 = 23.69 
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Table 11 Distribution of SFLT levels of the study population according to 
pre-eclampsia (n=90) 
 
 
Blood pressure N 
MeanSFLT 
levels 
Std. Deviation 
95% Confidence Interval for Mean 
Lower Bound Upper Bound 
Normal 68 134.29 25.534 128.11 140.47 
Pre-eclampsia 17 220.94 72.994 183.41 258.47 
Eclampsia 5 815.40 333.678 401.08 1229.72 
Total 90 188.50 176.005 151.64 225.36 
 
ANOVA test was applied to test the difference in mean SFLT levels between the 
groups followed by Bonferroni post-Hoc test for inter-group comparisons. 
 
 
ANOVA test 
p value <0.001* 
F statistic 165.329 
Degree of freedom 2 
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Bonferroni Post-Hoc test 
 
Comparison groups  Mean Difference p value 
95% Confidence Interval 
For Mean Difference 
Normal BP vs Pre-eclampsia -86.647 0.001 -140.43 to -32.87 
Normal BP vs Eclampsia -681.106 <0.001 -773.01 to -589.20 
Pre-eclampsia vs Eclampsia -594.45 <0.001 -695.36 to 493.56 
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Table 12 Distribution of various parameters of the study population 
according to gestational age(n=90) 
 
Difference between 17 
weeks and 40 weeks 
Mean 
difference 
(17 – 40 
weeks) 
Std. 
Deviation 
95% Confidence Interval of the 
Difference 
Paired “t” test 
p value 
Lower Upper 
Maternal Weight -12.311 2.048 -12.74 -11.88 <0.001 
Systolic pressure -3.356 12.233 -5.918 -0.793 0.011 
Diastolic pressure -2.278 9.701 -4.310 -0.246 0.028 
SGPT levels -2.922 8.106 -4.620 -1.224 0.001 
SGOT levels -2.000 7.733 -3.620 -0.380 0.016 
Serum creatinine levels 0.2400 2.9073 -0.3689 0.8489 0.436 
Platelet count 10332.0 18754.9 6403.9 14260.2 <0.001 
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Table 13: Pearson Correlation matrix between various parameters and 
SFLT levels (n=90) 
 
 
SFLT Age 
Systolic 
BP Rise 
Diastolic 
BP Rise 
SGPT 
Rise 
SGOT 
Rise 
Serum 
Creatin
ine fall 
Platelet 
count 
fall 
SFLT 1 
     
 
 
Age -0.033 1 
    
 
 
Systolic 
BP Rise 
0.333* 0.015 1 
   
 
 
Diastolic 
BP Rise 
0.304* -0.088 0.776* 1 
  
 
 
SGPT 
Rise 
0.835* -0.097 0.314* 0.308* 1 
 
 
 
SGOT 
Rise 
0.849* -0.01 0.334* 0.307* 0.836* 1  
 
Serum 
Creatinin
e fall 
-0.109 0.098 -0.224* -0.213* -0.175 0.079 1 
 
Platelet 
count fall 
-0.695* -0.027 -0.094 -0.015 -0.761* -0.771* 0.01 1 
 
*Correlation significant at 0.05 level 
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Table 14: Pearson Correlation matrix between SFLT levels and various 
parameters among cases and controls (n=90) 
Variables 
Cases (n=20) Controls (n=45) 
Pearson 
Correlation 
p value 
Pearson 
Correlation 
p value 
SFLT and Age 0.123 0.586 -0.243 0.046 
SFLT and Rise in systolic BP -0.334 0.129 -0.225 0.065 
SFLT and Rise in diastolic BP -0.326 0.059 -0.099 0.420 
SFLT and Rise in ALT 0.861 <0.001 -0.007 0.954 
SFLT and Rise in AST 0.841 <0.001 0.210 0.086 
SFLT and Fall in serum creatinine 0.006 0.978 0.046 0.712 
SFLT and Fall in platelet count -0.748 <0.001 -0.107 0.385 
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Table 15 Logistic regression of various factors with Occurrence of pre-
eclampsia or eclampsia as dependent variable (n=90) 
INDEPENDENT 
VARIABLE (N) 
Odds Ratio (95% 
CI) 
p value 
Adjusted Odds Ratio 
(95% CI) 
p value 
 
SFLT levels (pg/ml) 
 
1.049 
(1.021 to 1.078) 
0.001 1.048 (1.012 to 1.085) 0.008 
Age (in years) 
 
0.898 
(0.726 to 1.112) 
0.323 0.810 (0.494 to 1.330) 0.406 
Mean Weight gain 
during pregnancy (in 
kg) 
1.563 
(1.150 to 2.126) 
0.004 2.233 (1.088 to 4.584) 0.029 
Mean Rise in SGPT 
during pregnancy 
1.349 
(1.134 to 1.605) 
0.001 0.887 (0.630 to 1.247) 0.489 
Mean rise in SGOT 
during pregnancy 
1.334 
(1.133 to 1.571) 
0.001 1.189 (0.816 to 1.733) 0.367 
Fall in Platelet count 
during pregnancy 
0.999974 
(0.999950 to 
0.999999) 
0.040 
1.000172 (1.000042 to 
1.000303) 
0.010 
 
Nagelkerke’s Pseudo R square for multivariate model: 79.8% 
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DISCUSSION 
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DISCUSSION 
“Hypertensive disorders of pregnancy”  are  considered to be one of 
the major health problem worldwide, causing an increased  perinatal and 
maternal morbidity and mortality
65
. Numerous  complex mechanisms play an 
important role in trophoblastic-endothelial dysfunction which includes  altered 
nitric oxide production, lipid and protein oxidation, anti angiogenic factors and 
adhesion molecules. All these factors can be  suggested as the etiopathogenesis 
of Preeclampsia. 
Increase in  placental derived “soluble fms-like tyrosine kinase 1’ 
(sFlt-1) or the “soluble vascular endothelial growth factor (VEGF) receptor 1” 
are responsible for the signs and symptoms of Preeclampsia, and increased  
levels of these circulating markers are associated with  Preeclampsia. The 
incidence of gestational  hypertension in developing countries and the highly 
industrialized world is similar but incidence of Preeclampsia & Eclampsia are 
higher in developing countries due to poor antenatal care and lack of education.  
The following factors may help to improve maternal and perinatal outcomes  
 
1. Early detection of high-risk individuals  by trained personnel 
2. Timely referral to  tertiary centres  
3. Early and timely treatment of Preeclampsia cases   
4. Correct training of the mothers about fertility age and the importance of 
care during pregnancy  
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In our study ,  we focused only on primigravida, because nulliparity 
itself is a main  risk factor for the development of   Preeclampsia. 
If we look into distribution of study population according to Preeclampsia and 
SFLT levels through  Pearson’s Chi-square with continuity correction( 69.348, 
p value: <0.001), there is a statistically significant association between elevated 
SFLT levels and occurrence of Preeclampsia with 86.4% of Pre-eclampsia & 
Eclampsia patients showing elevated SFLT levels. 
In our study population , Preeclampsia was present in 19% of subjects and 
Eclampsia  in 5.6% of the subjects. 
There is a statistically significant positive linear correlation between SFLT 
levels and levels of Systolic BP, Diastolic BP, ALT and AST i.e., an increase in 
SFLT level is associated with corresponding increase in these parameters . 
 
There is a statistically significant negative linear correlation between SFLT 
levels and Platelet count. i.e, an increase in SFLT levels with corresponding 
decrease in Platelet count . 
 
 Table 1 depicts age distribution of study population  showing  mean age of the 
population as 25 years with 57.8%  of population belonging  to 21-25 years  age 
group. 
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Table 2  shows distribution of mean maternal weight in kg during various 
antenatal period .  The mean weight gain during pregnancy  is 12.3 kg in our 
study 
Table 3 shows  distribution of the Mean maternal blood pressure during various 
antenatal periods  revealing   3 mmHg raise in mean systolic pressure and 2 
mmHg in mean diastolic pressure  during pregnancy.  
Various studies show that all preeclamptic women had significantly higher 
levels of sFlt-1  at gestational ages where their blood pressure was within 
normal limits. 
 
Table 4 shows distribution of the mean maternal levels of transaminases during 
various antenatal periods. The mean ALT levels are  raised by approximately 3 
units and  AST  levels  by 2 units during pregnancy.  
During the course of pregnancy from 17 weeks to term, many parameters like 
maternal Weight, systolic pressure, diastolic pressure, ALT and AST levels 
increased with  Eclampsia  corresponding  to gestational age and this elevation 
during pregnancy is statistically significant. 
Table 5  shows  distribution of the mean maternal levels of Serum creatinine 
during various antenatal periods .It shows a decline in mean creatinine levels  
initially during pregnancy and then raised marginally towards term in eclampsia. 
The difference of mean serum creatinine levels between 17 weeks and term was 
not statistically significant. 
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Table 6  shows  distribution of the Mean maternal platelet count during various 
antenatal periods. The mean maternal platelet count showed a gradual decline 
with increase in gestational age in eclampsia patients which is  statistically 
significant. 
 
Table 7 shows distribution of the proteinuria during various antenatal periods. 
There is increased proteinuria with corresponding gestational age in 
preeclamptic and eclamptic patients. 
 
Table 8 shows distribution of the “soluble fms like tyrosine kinase 1” in the 
study population .The “soluble fms like tyrosine kinase 1” levels were elevated 
in 21% of the subjects with a mean level of 188.5 ± 176.0 pg/ml.  
 
Table 9 shows the presence of  Pre-eclampsia  in 19% of subjects and 
eclampsia  in 5.6% of the subjects in our study. 
 
Table 10 Distribution of the study population according to pre-eclampsia and 
SFLT levels shows  Relative risk = 100/4.22 = 23.69 
Subjects with elevated SFLT levels have 23 times higher risk of developing Pre-
eclampsia & Eclampsia in comparison to Subjects with normal SFLT levels. 
During univariate analysis, an increase in variables like SFLT levels, mean 
weight gain  (in kg), mean rise in ALT & AST levels during pregnancy were 
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significantly associated with raised  risk of developing pre-eclampsia and 
eclampsia.   
 
During multivariate analysis, there was statistically significant increased risk of 
pre-eclampsia with rise in SFLT levels, rise in mean weight gain and fall in 
platelet count. But the mean rise in ALT & AST levels during pregnancy was 
not significant. 
Nagelkerke’s Pseudo R Square shows that in the multivariate model, 79.8% of 
variability in the occurrence of pre-eclampsia can be explained by the variables 
in the model. 
ANOVA test was applied to test the difference in mean SFLT levels 
between the groups followed by Bonferroni post-Hoc test for inter-group 
comparisons. ANOVA test showed that there is a statistically significant 
difference in the mean SFLT levels between the 3 groups according to maternal 
blood pressure. 
Bonferroni test showed that the difference in mean SFLT levels 
between all the groups was statistically significant (p value <0.05) and that mean 
SFLT levels increases with increase in blood pressure and occurrence of 
eclampsia. 
Moreover, mean SFLT levels between the groups pre-eclampsia vs eclampsia 
was also statistically significant (p value <0.05) as SFLT levels were raised 
remarkably in cases of eclampsia. 
 
96 
 
 
 
 
 
 
 
 
 
 
 
CONCLUSION 
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CONCLUSION    
              From this study, It is found that the primigravida  with increased serum 
sFlt levels had  developed Preeclampsia in the later pregnancy and few of them 
developed Eclampsia  .  So , serum sFlt levels can be used to predict the 
occurrence of both Preeclampsia and progression To Eclampsia. 
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FUTURE  SCOPE OF THIS STUDY: 
 
                      Till date the only means of treating Preeclampsia is delivery. 
Many nonspecific interventions like using  antihypertensive agents have been 
tried, but with limited success.  There is less evidence to support whether these 
interventions can resolve the clinical manifestations or prevent them from 
developing. Also there  is no data whether these interventions can prolong a 
preterm pregnancy complicated by Preeclampsia . The factors responsible for 
the  pathogenesis of Preeclampsia is not clear , making new treatment strategies 
impossible.  
In view of early diagnosis of this condition , many new  soluble 
angiogenic are being discovered  which can be used either in isolation or 2 or 3 
markers can be combined and used in predicting or early diagnosis of 
Preeclampsia. Hence predicting Preeclampsia or early diagnosis of Preeclampsia  
by using these markers can help in development of new treatment modalities 
There is only limited success by removing toxic circulating factors 
responsible for Preeclampsia by either hemodialysis or plasmapheresis.  But 
none of them have prolonged a preterm pregnancy complicated by 
Preeclampsia. Circulating sFlt-1 accounts for less than 20% of the total body 
sFlt-1 burden.  Creating a selective adsorption column with a  concentration 
gradient may increase the  removal of these toxic substances.. 
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LIMITATIONS  OF THE STUDY 
               In  view of diagnosing the condition , the development of soluble 
angiogenic markers discussed above  help  in the screening  and early diagnosis 
of Preeclampsia. Most of the studies which support the use of these markers in 
screening and in early diagnosis  are retrospective.  There is definitely a need for 
more longitudinal prospective studies  to substantiate their role as a reliable 
marker in identifying  women at  risk and in early diagnosis in those who 
develop Preeclampsia  
52
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MASTERCHART 
SI  NO AGE WEEKS 
  
WEIGHT 
  
BLOODPRESSURE 
     
ALT 
 
   
1 2 3 4 17-20    21-28   29-36    36-40 POSTNATAL 1 2 3 4 
1 22 18 45 47 49 55 122/86 130/88 124/88 148/106 130/86 33 36 28 37 
2 23 19 53 53 60 65 120/89 106/70 116/80 146/100 120/89 30 27 23 24 
3 27 18 55 56 62 68 116/80 104/76 112/80 112/80 126/80 23 28 24 25 
4 25 17 60 61 66 73 112/80 90/60 110/76 110/76 112/86 28 29 25 26 
5 25 18 65 66 73 79 110/76 92/66 106/86 150/110 110/76 29 27 27 24 
6 24 18 53 57 60 65 130/86 122/80 116/86 140/90 120/86 32 33 37 36 
7 28 19 55 56 62 68 116/80 104/76 112/80 112/80 106/80 25 23 28 24 
8 24 18 53 57 60 65 130/86 122/80 116/86 140/90 136/86 32 33 37 36 
9 21 18 65 66 70 75 120/76 116/70 106/80 116/80 120/60 26 24 28 24 
10 26 18 60 60 66 73 106/80 100/60 122/80 128/80 116/80 24 26 24 26 
11 23 19 66 66 73 79 116/80 104/76 112/80 112/80 106/80 25 28 22 28 
12 29 17 65 65 70 75 124/86 146/100 160/106 140/92 124/90 35 45 68 56 
13 30 18 65 65 69 75 120/89 106/70 116/80 116/80 120/89 26 24 28 24 
14 28 19 60 61 66 73 106/80 104/76 112/80 112/80 106/80 24 26 24 26 
15 24 18 65 66 70 74 116/80 104/86 112/80 102/80 116/80 25 28 22 28 
16 22 19 58 64 68 72 126/88 124/86 112/88 140/90 126/88 28 37 32 33 
17 23 18 55 56 62 68 120/89 106/70 116/80 116/80 106/80 30 27 23 24 
18 24 17 50 51 56 63 116/80 104/76 90/80 112/80 106/70 23 28 24 25 
19 25 18 60 61 66 73 106/80 104/78 112/80 104/80 106/80 28 29 25 26 
20 22 19 56 58 62 68 120/84 114/76 124/96 144/96 120/84 33 37 36 33 
21 21 19 60 61 66 73 120/89 106/70 116/80 116/80 116/80 24 26 23 28 
22 23 20 65 66 70 74 116/80 104/76 112/80 112/80 116/80 22 28 28 29 
23 28 18 64 66 73 77 126/86 116/86 124/90 152/100 126/86 28 37 36 28 
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24 30 19 60 61 66 73 106/80 100/60 122/80 128/80 120/89 25 29 25 26 
25 26 18 60 61 66 73 116/80 104/76 112/80 112/80 116/80 23 28 24 25 
26 27 20 64 65 70 74 124/86 144/102 156/110 132/86 124/86 38 42 61 66 
27 26 18 58 57 62 68 120/89 106/70 116/80 116/80 120/89 23 28 24 25 
28 23 19 60 61 66 73 116/80 104/76 112/80 112/80 120/89 28 29 25 26 
29 28 18 60 61 66 73 106/80 100/60 122/80 128/80 106/80 29 27 27 24 
30 29 19 52 54 61 70 126/86 134/88 134/94 144/108 126/86 33 36 32 37 
31 25 17 65 65 69 75 120/89 90/70 106/80 116/80 106/70 30 27 23 24 
32 26 18 60 61 66 73 116/80 104/76 112/80 112/80 116/80 23 28 24 25 
33 23 18 65 66 70 74 120/89 106/70 116/80 116/80 120/89 28 29 25 26 
34 25 19 55 60 64 70 126/80 116/86 144/90 156/110 126/80 33 36 38 40 
35 26 18 60 61 66 73 112/80 90/60 110/76 110/76 106/70 25 29 25 26 
36 26 18 60 61 66 73 116/80 104/76 112/80 112/80 118/80 30 27 23 24 
37 24 19 64 64 69 75 132/86 156/100 146/110 140/94 132/86 33 44 65 70 
38 25 18 55 56 62 68 116/80 104/76 112/80 112/80 120/89 24 26 23 28 
39 25 19 60 61 66 73 112/80 90/60 110/76 110/76 106/70 22 28 28 29 
40 28 18 60 61 66 73 112/80 90/60 110/76 116/76 122/80 24 25 24 26 
41 27 19 55 56 62 68 112/80 90/60 110/76 110/76 112/80 24 28 24 25 
42 25 18 66 66 71 77 128/88 144/100 140/110 146/100 128/88 34 43 66 69 
43 26 18 65 65 69 75 112/80 90/60 110/76 110/76 112/80 30 27 23 24 
44 27 19 60 61 66 73 116/80 104/76 112/80 112/80 106/70 23 28 24 25 
45 23 19 65 66 70 74 112/80 90/60 110/76 110/76 116/80 28 29 25 26 
46 22 18 55 63 68 72 130/88 124/88 140/96 154/110 130/88 32 36 39 40 
47 21 19 55 56 62 68 126/80 104/76 112/80 112/80 126/80 24 26 23 28 
48 28 18 60 61 66 73 112/80 90/60 110/76 108/76 116/80 22 28 28 29 
49 28 19 60 61 66 73 106/80 104/76 112/80 112/80 106/80 24 26 24 26 
50 27 18 55 56 62 68 1180 90/60 110/76 110/76 112/80 24 28 24 25 
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51 26 18 58 65 69 74 130/78 126/88 146/96 144/110 130/78 32 33 38 39 
52 26 19 60 61 66 73 120/89 106/70 106/80 116/80 106/70 26 24 28 24 
53 23 18 65 66 73 79 116/80 104/76 112/80 122/80 116/80 24 26 24 26 
54 24 18 55 56 62 68 112/80 90/60 110/76 110/76 112/80 25 28 22 28 
55 23 18 57 60 64 70 120/88 124/88 146/96 150/110 120/88 30 34 39 39 
56 22 19 53 53 60 65 126/80 104/76 96/80 112/80 126/76 25 24 26 24 
57 23 18 55 56 62 68 112/80 90/60 110/76 108/76 116/80 22 28 25 29 
58 23 20 65 66 70 74 116/80 104/76 112/80 112/80 116/80 22 28 28 29 
59 21 18 58 59 65 71 122/86 140/100 148/110 146/96 122/86 32 47 67 69 
60 26 19 60 61 66 73 116/80 104/76 112/80 102/80 126/80 24 28 24 25 
61 27 18 54 56 60 72 130/88 124/88 140/96 154/110 130/88 32 36 39 40 
62 28 19 60 62 66 72 106/80 104/76 112/70 112/80 104/80 26 24 28 24 
63 21 18 65 65 69 75 102/80 96/60 110/86 110/76 102/80 24 26 24 26 
64 22 19 60 61 66 73 116/80 104/76 102/70 112/80 106/80 25 28 22 28 
65 23 18 65 66 70 74 112/80 90/60 110/76 110/76 102/80 25 24 26 24 
66 25 19 58 65 69 74 130/88 126/88 146/96 144/110 130/88 32 33 38 39 
67 26 18 60 61 66 73 116/80 104/76 112/80 112/80 118/80 30 27 23 24 
68 21 17 65 65 73 79 102/80 106/60 110/76 110/86 112/80 23 28 24 25 
69 26 17 60 61 66 73 116/80 104/76 112/80 112/80 116/80 28 29 25 26 
70 23 18 57 60 68 72 130/88 124/88 140/96 154/110 130/88 32 36 39 40 
71 25 18 60 61 65 73 124/80 100/76 112/80 112/80 114/80 24 28 24 25 
72 25 17 65 64 69 73 122/80 108/60 100/76 106/76 126/80 24 26 24 24 
73 27 19 60 61 66 73 116/80 104/76 112/80 112/80 106/70 23 28 24 25 
74 26 18 60 61 66 73 116/80 104/76 112/80 112/80 118/80 30 27 23 24 
75 21 19 67 66 68 75 116/80 104/76 122/80 112/80 106/80 24 30 27 23 
76 26 19 60 61 66 73 120/89 100/70 116/80 116/80 106/89 25 23 28 24 
77 25 18 65 66 70 74 116/80 104/76 112/80 110/80 126/80 24 26 24 24 
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78 24 17 50 51 56 63 116/80 104/76 90/80 112/80 106/70 23 28 24 25 
79 28 18 65 65 69 75 116/80 100/76 112/80 112/80 126/80 25 24 26 24 
80 21 19 59 60 64 68 116/80 104/76 100/80 112/80 118/80 24 28 24 25 
81 26 18 65 66 70 74 112/80 90/60 110/76 110/76 122/80 24 30 27 23 
82 25 17 65 65 69 75 120/89 90/70 106/80 116/80 106/70 30 27 23 24 
83 24 19 60 60 65 73 120/89 106/70 116/80 116/80 120/76 26 24 28 24 
84 25 18 55 56 62 68 126/80 104/76 112/80 122/80 116/80 24 26 24 26 
85 26 19 60 61 66 73 116/80 104/86 112/80 116/80 106/80 25 28 22 28 
86 23 18 55 56 62 68 112/80 90/60 110/76 108/76 116/80 22 28 25 29 
87 28 18 60 61 66 73 112/80 90/60 110/76 116/76 122/80 24 25 24 26 
88 25 18 65 66 70 75 116/80 104/76 90/80 112/80 118/80 26 24 26 24 
89 23 18 57 60 68 72 130/88 124/88 140/96 154/110 130/88 32 36 39 40 
90 28 19 60 61 66 73 116/80 104/76 112/80 112/80 126/80 24 28 24 25 
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MASTER CHART 
 
  
AST 
  
SERUM 
CREATININE 
    
PLATELET 
COUNT 
   
URINE  
PROTEIN 
 
SFLT 
pg/ml 
1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 
32 33 37 34 0.9 1.1 0.8 0.9 1,50,085 1,50,069 1,55,343 1,56,324 nil nil nil 1+ 203 
26 24 28 24 0.6 0.8 0.8 1 1,55,678 1,56,789 1,55,769 1,55,655 nil trace trace 2+ 78 
24 26 24 26 0.8 0.9 0.9 0.8 1,54,356 1,53,678 1,54,324 1,52,455 nil nil nil nil 88 
25 28 22 28 0.9 0.9 0.8 0.9 1,67,895 1,51,234 1,54,673 1,51,234 trace nil nil nil 76 
27 23 26 26 0.9 0.9 0.8 0.9 1,56,784 1,54,678 1,55,678 1,56,456 nil nil 1+ 2+ 97 
33 36 28 37 0.9 0.8 1 0.8 1,50,567 1,60,198 1,60,678 1,50,564 nil nil nil 1+ 187 
27 27 24 27 0.8 0.9 0.9 0.8 1,67,895 1,51,234 1,54,673 1,51,234 nil nil nil nil 102 
33 36 28 37 0.9 0.8 1 0.8 1,50,567 1,50,198 1,50,678 1,50,564 nil nil nil 1+ 201 
30 27 23 24 0.8 0.9 0.9 0.8 1,55,678 1,56,789 1,55,769 1,55,655 nil trace nil nil 112 
23 28 24 25 0.9 0.9 0.8 0.9 1,54,356 1,53,678 1,54,324 1,52,455 nil nil nil nil 79 
28 29 25 26 0.9 0.9 0.8 0.9 1,67,895 1,51,234 1,54,673 1,51,234 nil nil nil nil 156 
38 46 69 61 0.9 1 1.2 1.3 1,60,623 1,60,000 96,000 80000E NIL 2+ 2+ 4+ 639 
23 28 24 25 0.6 0.8 0.8 1 1,55,678 1,56,789 1,55,769 1,55,655 nil nil nil nil 145 
28 29 25 26 0.8 0.9 0.9 0.8 1,54,356 1,53,678 1,54,324 1,52,455 trace nil nil nil 123 
29 27 27 24 0.9 0.9 0.8 0.9 1,67,895 1,51,234 1,54,673 1,51,234 nil nil nil nil 88 
33 37 36 33 0.9 1.1 0.9 0.8 1,58,095 1,66,579 1,55,685 1,76,069 trace nil nil nil 185 
26 24 28 24 0.6 0.8 0.8 1 1,55,678 1,56,789 1,55,769 1,55,655 nil nil nil nil 134 
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24 26 24 26 0.8 0.9 0.9 0.8 1,54,356 1,53,678 1,54,324 1,52,455 nil nil nil nil 160 
25 28 22 28 0.9 0.9 0.8 0.9 1,67,895 1,51,234 1,54,673 1,51,234 trace nil nil nil 155 
37 32 33 33 0.7 0.8 1.2 1 1,56,678 1,67,059 1,45,075 1,57,069 nil nil nil 1+ 195 
25 29 25 26 0.6 0.8 0.8 1 1,67,895 1,51,234 1,54,673 1,51,234 nil nil nil nil 167 
25 23 28 24 0.8 0.9 0.9 0.8 1,54,356 1,53,678 1,54,324 1,52,455 trace nil nil nil 143 
37 32 33 38 0.9 1 0.9 0.9 1,54,035 1,57,658 1,67,565 1,57,095 nil nil nil 2+ 243 
27 27 24 27 0.8 0.9 0.9 0.8 1,67,895 1,51,234 1,54,673 1,51,234 nil nil nil nil 89 
28 29 25 26 0.9 0.9 0.8 0.9 1,54,356 1,53,678 1,54,324 1,52,455 trace nil nil nil 79 
35 44 66 61 0.8 0.9 1 1.1 1,60,532 98,654 60000E 1,00,654 TRACE 1+ 4+ 4+ 727 
26 24 28 24 0.6 0.8 0.8 1 1,55,678 1,56,789 1,55,769 1,55,655 nil nil nil nil 89 
24 26 24 26 0.8 0.9 0.9 0.8 1,54,356 1,53,678 1,54,324 1,52,455 trace nil nil nil 167 
25 28 22 28 0.6 0.8 0.8 1 1,67,895 1,51,234 1,54,673 1,51,234 nil nil nil nil 155 
24 33 32 28 0.9 0.8 1.1 0.9 1,76,676 1,71,059 1,56,775 1,67,769 nil trace nil 1+ 192 
23 28 24 25 0.9 0.9 0.8 0.9 1,55,678 1,56,789 1,55,769 1,55,655 nil nil nil nil 132 
28 29 25 26 0.9 0.9 0.8 0.9 1,54,356 1,53,678 1,54,324 1,52,455 trace nil nil nil 79 
29 27 27 24 0.6 0.8 0.8 1 1,67,895 1,51,234 1,54,673 1,51,234 nil nil nil nil 134 
32 36 36 40 0.8 0.9 1 1.2 1,56,735 1,67,558 1,56,265 1,65,095 nil nil 1+ 2+ 256 
25 23 28 24 0.8 0.9 0.9 0.8 1,67,895 1,51,234 1,54,673 1,51,234 nil nil nil nil 123 
26 24 28 24 0.6 0.8 0.8 1 1,55,678 1,56,789 1,55,769 1,55,655 nil nil nil nil 133 
33 53 65 66 7 0.8 1 1.1 1,60,456 1,60,423 99,657 67,567 E TRACE 2+ 3+ 4+ 648 
26 24 28 24 0.9 0.9 0.8 0.9 1,54,356 1,53,678 1,54,324 1,52,455 nil nil nil nil 145 
24 26 24 26 0.9 0.9 0.8 0.9 1,67,895 1,51,234 1,54,673 1,51,234 trace nil nil nil 98 
28 24 25 24 0.8 0.9 0.9 0.8 1,54,356 1,53,678 1,54,324 1,52,455 nil nil nil nil 132 
22 28 25 29 0.8 0.9 0.9 0.8 1,67,895 1,51,234 1,54,673 1,51,234 nil nil nil nil 167 
34 48 66 68 0.8 0.9 0.9 0.9 1,50,423 1,50,438 56000E 86,007 NIL 2+ 4+ 4+ 1409 
28 24 25 26 0.9 0.9 0.8 0.9 1,55,678 1,56,789 1,55,769 1,55,655 nil nil nil nil 143 
29 25 26 24 0.8 0.9 0.9 0.8 1,54,356 1,53,678 1,54,324 1,52,455 trace nil nil nil 135 
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22 28 25 29 0.6 0.8 0.8 1 1,67,895 1,51,234 1,54,673 1,51,234 nil nil nil nil 146 
32 36 38 40 0.8 0.8 1.1 1.2 1,50,535 1,00,538 1,00,267 1,00,495 nil nil 2+ 3+ 295 
27 23 24 28 0.9 0.9 0.8 0.9 1,54,356 1,53,678 1,54,324 1,52,455 nil nil nil nil 167 
28 24 25 29 0.9 0.9 0.8 0.9 1,67,895 1,51,234 1,54,673 1,51,234 trace nil nil nil 145 
28 29 25 26 0.8 0.9 0.9 0.8 1,54,356 1,53,678 1,54,324 1,52,455 trace nil nil nil 123 
25 24 26 24 0.8 0.9 0.9 0.8 1,67,895 1,51,234 1,54,673 1,51,234 nil nil nil nil 165 
32 32 39 42 0.8 0.9 1.1 1.1 1,70,545 1,72,538 1,70,467 1,70,495 nil nil 1+ 2+ 289 
28 24 25 26 0.8 0.9 0.9 0.8 1,54,356 1,53,678 1,54,324 1,52,455 nil nil nil nil 145 
29 25 26 24 0.8 0.9 0.9 0.8 1,67,895 1,51,234 1,54,673 1,51,234 trace nil nil nil 134 
25 29 25 26 0.6 0.8 0.8 1 1,67,895 1,51,234 1,54,673 1,51,234 nil nil nil nil 123 
32 25 28 22 28 0.9 1 1.2 1,50,535 1,60,739 1,70,267 1,55,495 nil nil 2+ 3+ 284 
25 23 28 24 0.8 0.9 0.9 0.8 1,54,356 1,53,678 1,54,324 1,52,455 nil nil nil nil 156 
24 30 27 23 0.8 0.9 0.9 0.8 1,67,895 1,51,234 1,54,673 1,51,234 trace nil nil nil 164 
25 23 28 24 0.8 0.9 0.9 0.8 1,54,356 1,53,678 1,54,324 1,52,455 trace nil nil nil 143 
35 53 67 67 0.9 0.8 0.9 1 1,50,325 1,50,002 98,897 67,800E NIL 2+ 2+ 4+ 654 
24 28 24 25 0.6 0.8 0.8 1 1,67,895 1,51,234 1,54,673 1,51,234 nil nil nil nil 147 
32 36 38 40 0.8 0.8 1.1 1.2 1,55,535 1,50,538 1,50,267 1,50,495 nil nil 2+ 3+ 138 
25 24 26 24 0.6 0.8 0.8 1 1,55,678 1,56,789 1,55,769 1,55,655 nil nil nil nil 89 
24 26 24 24 0.8 0.9 0.9 0.8 1,54,356 1,53,678 1,54,324 1,52,455 trace nil nil nil 139 
25 23 28 24 0.8 0.9 0.9 0.8 1,67,895 1,51,234 1,54,673 1,51,234 nil nil nil nil 87 
24 28 24 25 0.9 0.9 0.8 0.9 1,67,895 1,51,234 1,54,673 1,51,234 trace nil nil nil 153 
32 32 39 42 0.8 0.9 1.1 1.1 1,60,545 1,62,538 1,60,467 1,65,495 nil nil 2+ 3+ 333 
26 24 28 24 0.6 0.8 0.8 1 1,55,678 1,56,789 1,55,769 1,55,655 nil nil nil nil 133 
24 26 24 26 0.8 0.9 0.9 0.8 1,54,356 1,53,678 1,54,324 1,52,455 nil nil nil nil 147 
25 28 22 28 0.6 0.8 0.8 1 1,67,895 1,51,234 1,54,673 1,51,234 nil nil nil nil 154 
32 36 38 40 0.8 0.8 1.1 1.2 1,50,535 1,50,538 1,50,267 1,50,495 nil nil 2+ 3+ 290 
24 25 24 26 0.6 0.8 0.8 1 1,54,356 1,53,678 1,54,324 1,52,455 nil nil nil nil 134 
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26 24 26 24 0.8 0.9 0.9 0.8 1,67,895 1,51,234 1,54,673 1,51,234 nil nil nil nil 132 
29 25 26 24 0.8 0.9 0.9 0.8 1,54,356 1,53,678 1,54,324 1,52,455 trace nil nil nil 135 
26 24 28 24 0.6 0.8 0.8 1 1,55,678 1,56,789 1,55,769 1,55,655 nil nil nil nil 133 
26 24 28 24 0.6 0.8 0.8 1 1,55,678 1,56,789 1,55,769 1,55,655 nil nil nil nil 145 
24 26 24 26 0.8 0.9 0.9 0.8 1,54,356 1,53,678 1,54,324 1,52,455 nil trace nil nil 159 
25 28 22 28 0.9 0.9 0.8 0.9 1,67,895 1,51,234 1,54,673 1,51,234 nil nil nil nil 148 
24 26 24 26 0.8 0.9 0.9 0.8 1,54,356 1,53,678 1,54,324 1,52,455 nil nil nil nil 160 
30 27 23 24 0.8 0.9 0.9 0.8 1,55,678 1,56,789 1,55,769 1,55,655 nil nil nil nil 134 
23 28 24 25 0.9 0.9 0.8 0.9 1,54,356 1,53,678 1,54,324 1,52,455 nil nil nil nil 146 
28 29 25 26 0.6 0.8 0.8 1 1,67,895 1,51,234 1,54,673 1,51,234 nil nil nil nil 138 
23 28 24 25 0.9 0.9 0.8 0.9 1,55,678 1,56,789 1,55,769 1,55,655 nil nil nil nil 132 
25 24 26 24 0.8 0.9 0.9 0.8 1,55,678 1,56,789 1,55,769 1,55,655 nil nil nil nil 145 
24 25 24 26 0.9 0.9 0.8 0.9 1,54,356 1,53,678 1,54,324 1,52,455 nil nil trace nil 137 
26 24 26 24 0.6 0.8 0.8 1 1,67,895 1,51,234 1,54,673 1,51,234 nil nil nil nil 153 
24 30 27 23 0.8 0.9 0.9 0.8 1,67,895 1,51,234 1,54,673 1,51,234 trace nil nil nil 164 
28 24 25 24 0.8 0.9 0.9 0.8 1,54,356 1,53,678 1,54,324 1,52,455 nil nil nil nil 132 
24 26 24 25 0.9 0.9 0.8 0.9 1,67,895 1,51,234 1,54,673 1,51,234 nil nil nil nil 146 
32 36 38 40 0.8 0.8 1.1 1.2 1,50,535 1,50,538 1,50,267 1,50,495 nil nil 2+ 3+ 290 
25 24 26 24 0.8 0.9 0.9 0.8 1,67,895 1,51,234 1,54,673 1,51,234 nil nil nil nil 171 
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PROFORMA 
NAME OF THE PATIENT :                                                                        OP NO: 
 
AGE    : 
 
OCCUPATION  : 
 
ADDRESS   : 
 
COMPLAINTS  : 
 
PAST HISTORY  : 
 
PERSONAL HISTORY : 
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FAMILY HISTORY  : 
 
DRUG HISTORY  : 
 
GENERAL EXAMINATION:          
Ht:                Wt:            BMI:               BP:                 PR: 
 
 
 
 
 
 
SYSTEMIC EXAMINATION:      
                                            CVS:                                                   RS:                                                           
                                            ABD:                                                  CNS:                                                                                     
 
 
INVESTIGATIONS : 
 
1) SERUM  ALT 
2) SERUM AST 
3) SERUM CREATININE: 
4) PLATELET COUNT 
5) URINE PROTEIN 
6) SOLUBLE FMS LIKE TYROSINE KINASE 1  
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CONSENT FORM 
 
 
Dr. K.Manjukarthikeyani post graduate student in the department of 
Biochemistry, Thanjavur medical college, Thanjavur is doing a Study of soluble 
fms like tyrosine kinase 1 as predictive marker of pre ecalmpsia in primigravida. 
The procedures has been explained to me clearly. I understand that there are no 
risks involved in the above procedures. I hereby give my consent to participate 
in this study. The data obtained here may be used for research and publication. 
  
Signature : 
Name: 
Place:  
 
 
 
